Product Information
CLINDAMYC-BNZ PEROX 1.2-3.75% is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $2.3440 per GM under NDC 45802038301. Its NADAC has been published 104 times since Oct 9, 2024.
FDA first approved this application on Aug 20, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
37.5; 10 mg/g; mg/g
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802038301
Classification
Generic
Dosage Form
GEL
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATEApproval Type
Generic (ANDA)
FDA Application
ANDA209610FDA Approved
8/20/2024
TE Code
AB
On Market Since
9/20/2024
Pharmacological Classes
Price Statistics
The NADAC for CLINDAMYC-BNZ PEROX 1.2-3.75% has been published 104 times since Oct 9, 2024, and over the history we have for it it has declined 54.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.3440 per GM |
|---|---|
| All-time high | $5.9100 (Nov 13, 2024) |
| All-time low | $2.3440 (Sep 23, 2026) |
| 52-week high | $4.6087 |
| 52-week low | $2.3440 |
| Median price | $4.0918 |
| Average price | $4.0035 |
| Largest weekly change | -22.2% (Apr 22, 2026) |
| Weeks tracked | 104 |
| Tracking since | Oct 9, 2024 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Clindamycin Phosphate and Benzoyl Peroxide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Lincosamide Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLINDAMYC-BNZ PEROX 1.2-3.75%?
The current National Average Drug Acquisition Cost (NADAC) for CLINDAMYC-BNZ PEROX 1.2-3.75%, manufactured by Padagis Israel Pharmaceuticals Ltd, is $2.3440 per GM (NDC 45802038301), effective Sep 30, 2026.
How has the price of CLINDAMYC-BNZ PEROX 1.2-3.75% changed over time?
Over the history we have for it, the NADAC for CLINDAMYC-BNZ PEROX 1.2-3.75% has declined 54.0%. It has been tracked across 104 weekly CMS publications since Oct 9, 2024.
What are the highest and lowest recorded NADAC prices for CLINDAMYC-BNZ PEROX 1.2-3.75%?
Since Oct 9, 2024, the NADAC for CLINDAMYC-BNZ PEROX 1.2-3.75% has ranged from a low of $2.3440 (Sep 23, 2026) to a high of $5.9100 (Nov 13, 2024), with a median of $4.0918 per GM.
Are there cheaper alternatives to CLINDAMYC-BNZ PEROX 1.2-3.75%?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CLINDAMYC-BNZ PEROX 1.2-3.75% in a comparable dosage form, but none are currently priced below it.
Who manufactures CLINDAMYC-BNZ PEROX 1.2-3.75%?
CLINDAMYC-BNZ PEROX 1.2-3.75% (NDC 45802038301) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.